Sun Pharma to acquire Organon in $11.75 billion all-cash deal
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Growth was broad-based across segments
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector
The system is powered by BrainSense technology, which has received approval from USFDA
Subscribe To Our Newsletter & Stay Updated